Tolerogenic Dendritic Cell Vaccine
Phase 1Vaccine
Tolerogenic Dendritic Cell Vaccine is one of 34 biologic programs targeting Type 1 Diabetes. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Mounjaro
Eli LillyApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ozempic
Novo NordiskPhase 3
Stelara
Johnson & JohnsonPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Tricor
JJagotec
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Diamox
TevaPhase 2
Kerendia
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 1 Diabetes1 trial
An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
Active, not recruiting·—·Phase 1·NCT04590872·6 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company
- CCity of Hope Medical Center